Hepatitis E Virus Infection in Patients with Systemic and Cutaneous Lupus Erythematosus

Int J Mol Sci. 2024 Oct 17;25(20):11162. doi: 10.3390/ijms252011162.

Abstract

Systemic lupus erythematosus (SLE) is a chronic autoimmune disease characterized by a multifactorial etiology in which genetic and environmental factors interplay. An exclusively cutaneous condition has been described and defined as cutaneous lupus erythematosus (CLE). In Italy, a nationwide blood donor survey found an overall HEV prevalence of 8.7%, with an interregional variation from 2.2% to 22.8%. In this study, we aimed to estimate HEV seroprevalence in a cohort of patients affected by SLE and CLE attending the Lupus Clinic, Sapienza University of Rome. Serum samples were tested for anti-HEV immunoglobulin Ig G and M antibodies using commercial enzyme-linked immunosorbent assay (ELISA) kits. Statistical analysis was performed. In total, 138 patients were enrolled, 92 (67%) affected by SLE and 46 by CLE. The prevalence of HEV infection was 23.9% in the CLE group and 7.6% in the SLE group. The anti-HEV+ prevalence was significantly more frequent in CLE. Some mechanisms may be linked to increased susceptibility to HEV such as a molecular mimicry associated with the CLE condition or with the skin compartment/skin self-antigens, as well as the involvement of the genetic background. Regarding the possible risk factors, no association was found, although, of note, the odds of HEV+ relative to contact with animals and to eating raw seafood were strongly higher than the unit in the CLE group.

Keywords: cutaneous lupus erythematosus; hepatitis E virus; serological and epidemiological evaluation; systemic lupus erythematosus.

MeSH terms

  • Adult
  • Aged
  • Female
  • Hepatitis Antibodies / blood
  • Hepatitis E virus / genetics
  • Hepatitis E virus / immunology
  • Hepatitis E* / complications
  • Hepatitis E* / epidemiology
  • Humans
  • Immunoglobulin G / blood
  • Immunoglobulin M / blood
  • Italy / epidemiology
  • Lupus Erythematosus, Cutaneous* / complications
  • Lupus Erythematosus, Cutaneous* / epidemiology
  • Lupus Erythematosus, Cutaneous* / immunology
  • Lupus Erythematosus, Systemic* / complications
  • Lupus Erythematosus, Systemic* / epidemiology
  • Male
  • Middle Aged
  • Prevalence
  • Risk Factors
  • Seroepidemiologic Studies

Substances

  • Immunoglobulin G
  • Immunoglobulin M
  • Hepatitis Antibodies